Back to Authors

Pandit, Urvashi

Mayo Clinic

Centers for Disease Control and Prevention

Citations 1

Accuracy of Case-Based Seroprevalence of SARS-CoV-2 Antibodies in Maricopa County, Arizona
Jehn, Megan, Pandit, Urvashi, Sabin, Susanna, Tompkins, Camila, White, Jessica, Kaleta, Erin, Dale, Ariella P., Ross, Heather M., McCullough, J. Mac, Pepin, Susan, Kenny, Katherine, Sanborn, Heidi, Heywood, Natalie, Schnall, Amy H., Lant, Timothy, Sunenshine, Rebecca, Jehn, Megan , Pandit, Urvashi, Sabin, Susanna J. , Tompkins, Camila, White, Jessica, Kaleta, Erin, Dale, Ariella P., Ross, Heather M., McCullough, J. Mac, Pepin, Susan, Kenny, Katherine, Sanborn, Heidi, Heywood, Natalie, Schnall, Amy H., Lant, Timothy, Sunenshine, Rebecca

American Journal of Public Health | December 22, 2021 | Volume: 112 | Issue: 1 | Pages: 38-42

10.2105/ajph.2021.306568 Get It

We conducted a community seroprevalence survey in Arizona, from September 12 to October 1, 2020, to determine the presence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We used the seroprevalence estimate to predict SARS-CoV-2 infections in the jurisdiction by applying the adjusted seroprevalence to the county’s population. The estimated community seroprevalence of SARS-CoV-2 infections was 4.3 times greater (95% confidence interval = 2.2, 7.5) than the number of reported cases. Field surveys with representative sampling provide data that may help fill in gaps in traditional public health reporting. (Am J Public Health. 2022;112(1):38–42. https://doi.org/10.2105/AJPH.2021.306568 )